Shennon Biotechnologies raised $12 million and appointed Cyril Konto as CEO to drive its TCELERATOR platform and oncology pipeline forward. The company said it is shifting from platform-building toward development-stage execution, with three disclosed T-cell engager programs (SBT-121, SBT-201, and SBT-425). Management framed the financing as runway for moving a development candidate toward an IND filing and Phase I clinical development within about two years, while continuing expansion of its human datasets and safety assessment approach. For investors and peers, the package highlights continued capital appetite for functional cell-engager discovery platforms as companies try to compress time-to-clinic through high-throughput profiling and binder/T-cell safety modeling.